Mohlala o kopantsoeng o hahiloe bakeng sa limolek'hule tse kopanyang, eseng bakeng sa li-peptide tse tloaelehileng mananeong a DNA-to-IND
Tsela e kopantsoeng e hlalosoa ke polelo ea recombinant, le tlhaloso eo, e seng lekhalo ho fana ka litšebeletso, ke eng e behang li-peptide tsa maiketsetso ka ntle ho eona. Leqephe la lenaneo la Lonza le hlalosa ts'ebetso e le 'ngoe e hokahaneng ea CMC e tlisang nts'etsopele ea lisele, nts'etsopele ea ts'ebetso le tlhahiso, liteko tsa tlhahlobo le litokomane tsa taolo hammoho ka "ho fokotsa ho fana le ho hokahanya mesebetsi eohle ea CMC" (Leqephe la lenaneo la Lonza DNA-to-IND, e se nang nako, kgutlisitsoe 2026). Mohato o mong le o mong oa ketane eo o qala ka sele e tšoaelitsoeng.
Ka October 2026 katoloso e atolositse ketane e ts'oanang ho biologics e seng ea mAb, ho eketsa li-antibodies tsa bispecific, Liprotheine tsa Fc-fusion le lihlahisoa tse phahameng tsa lihlahisoa tsa lithethefatsi, le ho tsamaisa nts'etsopele ea tlhahiso e phahameng ea concentration pejana ho ts'ebetso (Keletso ea litaba tsa Lonza). Likarolo tsa limolek'hule tse bitsoang liforomo kaofela tse recombinant.
Lintlha tsa ho kena tsa lenaneo li tsoa ho tlhahlobo ea kaho ea li-vector le tlhahlobo ea tlhahiso ka DNA ho isa ho lithethefatsi tse chefo kapa sehlopha sa sehlahisoa sa lithethefatsi., DNA ho etsa lipatlisiso, banka e kholo kapa ea tlhahiso ea lisele, phetisetso ya selefounu kapa mokgoa o tiisitsoeng, le ntho e ngata ea lithethefatsi kapa sehlahisoa se hloekisitsoeng, ka khetho ea ho sebelisana ka botlalo ho IND kapa ho khefutsa ka mehato e hlalositsoeng (Leqephe la lenaneo la Lonza DNA-to-IND, e se nang nako, kgutlisitsoe 2026). Peptide e entsoeng ka lik'hemik'hale ha e na vector, ha ho na mohala oa sele 'me ha ho mohato oa phetisetso oa ho kena ho.
Linako tse boletsoeng ke barekisi li na le foreimi e tšoanang. Tafole ea bohlokoahali e thathamisa likhoeli tse tšeletseng ho tloha ka tatelano ea DNA ho ea ho IND/IMPD, DNA ho chefo ka mor'a likhoeli tse peli le ho tlosa kotsi pele ho nako 11 libeke, ka mongolo o botlaaseng ba leqephe o fokotsang tseko ea "ho tloha phetisong ea DNA ho isa ho phano ea li-module tsa CMC tse nolofaletsang IND. Linako tse tloaelehileng. Ho ipapisitsoe le lipehelo le lipehelo” (Leqephe la lenaneo la Lonza DNA-to-IND, e se nang nako, kgutlisitsoe 2026). Oache e qala nakong ea phetiso. Bakeng sa peptide e entsoeng ka lik'hemik'hale ka ho feletseng, Phetiso ea DNA ha se mohato oa bohlokoa oa ho qala.
Mekhahlelo e 'meli e hula moeli oa peptide ka tsela e fapaneng, 'me phapang ke k'hemistri
Tsela ea tlhahiso, litšobotsi tsa sehlahisoa, sesupo le matla li susumetsa tsela ea taolo. K'hemistri ea post-chain ke ntlha e le 'ngoe, eseng mofuta o le mong o etsang qeto ea hore na ke moralo ofe o sebetsang.
Mebuso e 'meli ebe e fapanyetsana moo peptide e fetotsoeng e lulang teng. Tataiso ea EMA e amohela lihlahisoa tse sirelelitsoeng tsa asiti ea L-amino, 'me maemong a nepahetseng likhechana tse khutšoane tsa peptide, joalo ka lisebelisoa tsa ho qala, but states that polypeptide fragments undergoing only limited further GMP modification, such as cyclisation or conjugation to non-peptide moieties like PEG chains, are intermediates rather than starting materials. It also treats an activated PEG derivative such as an NHS ester as an intermediate itself (EMA guideline, e sebetsang hantle 1 Phuptjane 2026).
FDA withdrew the 2021 guidance in July 2026. Modification or lipidation alone does not universally exclude a generic-drug pathway; assess sameness to the reference product, current product-specific guidance and the actual application requirements. FDA’s withdrawal and revised-draft update.
The EMA guideline addresses relevant synthetic-peptide and conjugation quality questions. FDA pathway eligibility must be assessed separately for the proposed product and reference drug; palo ea k'hemistri e ekelitsoeng ha e thehe molao o tloaelehileng oa ho kenyelletsa EMA / FDA.
Seo ho se hloeke le rekoto e khethehileng e hlileng e se hlokang ho peptide
Litlhaloso tsa peptide li ngotsoe ho tsoa lihlopheng tsa litšila tse ikhethileng tsa peptide le menyako., e sa fuweng ho tswa ho moralo ofe kapa ofe o bapileng. Mekhahlelo ea mabitso a tataiso ea EMA ke li-stereoisomers, tatellano ya ho hlakolwa, tatellano e nyenyefalitsoeng le tatelano ya ho kenya (Leqephe la ho fihla la tataiso ea EMA, e sebetsang hantle 1 Phuptjane 2026). Mehato eo EMA e supang hore e tla tsoa ho Ph. EUR. kakaretso ea monograph 2034: tlaleha ho se hloeke ka holimo 0.1%, tsebahatsa ka holimo 0.5%, tšoaneleha ka holimo 1.0%, e se nang palo e akaretsang ea palo bakeng sa litšila tse sa boleloang kapa tse amanang le peptide kaofela, tse behiloeng sehlahiswa ka ho kgetheha le ho lokafatsa taba ka nngwe (EMA guideline, e sebetsang hantle 1 Phuptjane 2026).
Peptide Wholesale Maemo a sa sebetseng a loketse ho boleloa ka ho hlaka, hobane ke mohloli o tloaelehileng oa phoso. Ke Q3A(R2) e beha tlaleho ho 0.05%, boitsebiso ka 0.10% kapa 1.0 mg/letsatsi le mangolo a thuto ho 0.15% kapa 1.0 mg / letsatsi bakeng sa tekanyo e phahameng ea letsatsi le letsatsi ka tlase kapa ka tlase 2 g/letsatsi (Ke Q3A(R2), ntlafatso ea hajoale). Linomoro tseo ha se meeli ea peptide, le tataiso ea EMA e bolela ka ho toba hore meeli ea Q3A "ha e sebetse" ho li-peptide tsa maiketsetso..
Conjugation e eketsa litšoaneleho tseo tlhaloso ea ketane feela e sa tsoeng. Tataiso ea EMA e hloka taolo ea peptide ea mahala e sa kopaneng le mofuta oa mahala oa conjugate moiety., joalo ka PEG ea mahala kapa linker, mme e bolela hore di-PEGylation, Multi-PEGylation le lihlahisoa tsa PEGylation tseo e seng tsa sebaka sa marang-rang li lokela ho laoloa ka mokhoa o lekaneng. (EMA guideline, e sebetsang hantle 1 Phuptjane 2026). E boetse e hloka hore mehato eohle ea motsoako oa mahareng ho tsoa ho thepa e hlalositsoeng ea ho qala e etsoe tlasa GMP, ka tlhaiso-leseling e felletseng ea tšebetso ho Mojule 3 Karolo 3.2.S.2.2.
Tataiso e tobileng e sa kenyelletseng li-peptide tsa maiketsetso ha se foreimi e lokelang ho fihleloa. ICH Q6B e hlalosa tlhaloso e le lethathamo la liteko, litšupiso tsa mekhoa ea ho hlahloba le mekhoa ea ho amohela, le lekhetho la eona la ho se hloeke le hahiloe bakeng sa polelo e kopanetsoeng: cell substrate-nkiloeng, seleng setso-nkiloeng le ho theosa le noka-nkiloeng (Ke Q6B, Mohato 4, 1999). Taxonomy eo ha e fetisetsoe ho solid-phase synthesis, moo litšila e leng mefuta ea enantiomeric le diastereomeric, li-amino acid tse sa sireletsehang ka mokhoa o itseng, dipeptides le ditshila tsa beta-alanyl (EMA guideline, e sebetsang hantle 1 Phuptjane 2026).
Moo setsebi se eketsang boleng: tlhahlobo ea monyetla pele tsela e lokisoa
Taba ea tlhahlobo ea pele ea ho khonahala ke lipalo, eseng khetho. Likopano tse mashome a mararo ho 99% kotulo e sebetsang e fana ka 0.99³⁰, hoo e ka bang 74% koketso pele ho tshireletso, qhetsola, tlhoekiso le tahlehelo ea ho itšehla thajana (Almanaka ea Pharma). Tatelano eo banyalani ba sa sebetseng hantle maemong a mararo e lahleheloa ke ho feta kamoo mohlala o bolelang esale pele, le metsoako ea tahlehelo e khutsitse ho fihlela boemo bo sa hloekang bo lekanngoa.
Ke ka lebaka leo khetho ea litsela e leng qeto e ikhethileng ka tatellano ho fapana le sethala sa kamehla. A 2025 tlhahlobo ea kalafo ea peptide ea kalafo le synthesis e tlaleha hore motsoako oa lik'hemik'hale o lumellana le li-peptide tsa 50 masalla kapa ka tlase ho moo, moo tatellano e fokoditsweng, racemisation le karabelo lehlakoreng hloka HPLC tlhoekiso, athe tlhabollo ya baeloji e dumellana le tatelano e telele empa e hlahisa Peptide 1 Moetsi liprotheine tsa lisele tse amohelang, li-endotoxins le ho tsoakana hampe (Zheng et al., Int. J. Mol. Sci., 2025). Tlhahlobo e tšoanang e hlokomela hore ho kheloha ho honyenyane ho latellanang ha amino acid, phetoho ea ka morao ho phetolelo kapa boemo ba litšila bo ka ama haholo ts'ebetso ea meriana, pharmacokinetics le immunogenicity.
Sekala se fetola lintlha tsa taolo, eseng feela boholo ba batch. Custom peptide synthesis spans milligrams bakeng sa ho sibolloa le litekanyetso tsa tlhahlobo, dikgerama bakeng sa ntshetsopele ya tshebetso, toxicology le mosebetsi oa pele oa bongaka, ligrama tse mashome ho isa ho tse makholo kapa ho pota kilogram ka beche bakeng sa lihlahisoa tsa kliniki le tsa niche, le lik'hilograma ho ea ho li-kilogram tse ngata ka beche bakeng sa API ea khoebo, ka tatelano, tlhophiso le litlhoko tsa bohloeki tse bohlokoa joalo ka boholo ba batch (Almanaka ea Pharma, 18 Mots'eanong 2026). Ho kopanya botlalo, boits'ireletso le boits'oaro ba ho qhetsola, moroalo wa ditshila, preparative tlhoekiso loadability le counter-ion kapa letsoai foromo ke lintlha tse etsang qeto ea hore na letšolo sekala, 'me li theko e tlaase ho feta ho lekoa pele tsela e notleloa.
Fetisitsoe, li-peptide tse ngotsoeng le tse kopantsoeng ke moo mohlala o kopantsoeng o emang teng
<sehlopha sa lipalo="chate ea blog" mokhoa="boholo ba bophara:640px;moeling:1.5rem auto;boholo ba fonte:12px;bophahamo ba mola:1.3;mmala:lefa"> <svg viewBox="0 0 560 380" mokhoa="boholo ba bophara: 100%; bophahamo: koloi; fonte-lelapa: 'Inter', tsamaiso-ui, sans-serif; mmala: #1e293b; --tjhate e kgutsitseng: #64748b;" karolo="img" aria-labelledby="2025-peptide-and-oligonucleotide-cdmo-revenue-split-title 2025-peptide-and-oligonucleotide-cdmo-revenue-split-desc"> <setaele> /* Mofani o kenya chate ho iframe eo bokamorao ba eona bo leng botšo, mme iframe ke sebopeho se fapaneng le chate, kahoo lihlopha tsa lebokose la litlhaku li ne li bonahala e le liforeimi tse ntšo ho e potoloha (tlhahiso 09-22). Tokomane e ka hare ho iframe e pepeneneng ka ho sa feleng; ho penta mona ho akaretsa bokamorao ba lintho, 'me ha chate e kentsoe ka mola sebakeng sena sena ha se amane le letho. Boloka li-angle brackets kantle ho boloko bona: setaele se kahare ho SVG se arotsoe joalo ka litaba tsa kantle ho naha, kahoo bracket e le 'ngoe e khelohileng e lahla molao o mong le o mong o ho eona. */ html, mmele { bokamorao: #ffffff; moeling: 0; } @media (e ratang-e fokotsehile: fokotsa) { * { animation: ha ho letho !bohlokoa; phetoho: ha ho letho !bohlokoa; } } </setaele> <hantle x="0" y="0" bophara="560" bophahamo="380" rx="8" tlatsa="#ffffff" /> <title id="2025-peptide-and-oligonucleotide-cdmo-revenue-split-title">2025 peptide le oligonucleotide CDMO karohano ea chelete</sehlooho> <desc id="2025-peptide-and-oligonucleotide-cdmo-revenue-split-desc">peptide le oligonucleotide CDMO karohano ea chelete: boleng ba Peptides, Li-oligonucleotides. 2025 peptide le oligonucleotide CDMO karohano ea chelete. lintlha tsa donut: Li-peptides 66.7; Oligonucleotides 33.3.Mohloli: Lipatlisiso tsa Grand View, Peptide & Oligonucleotide CDMO Market 2026.</desc> <mongolo x="280.0" y="29" mongolo-ankora="bohareng" boholo ba fonte="18" boima ba fonte="800" tlatsa="joaleMmala">2025 peptide le oligonucleotide CDMO karohano ea chelete</mongolo> <tsela d="M 238.00 93.00 A 92 92 0 1 1 158.23 230.83 L 192.91 210.91 A 52 52 0 1 0 238.00 133.00 Z" tlatsa="#f97316" /> <tsela d="M 158.23 230.83 A 92 92 0 0 1 238.00 93.00 L 238.00 133.00 A 52 52 0 0 0 192.91 210.91 Z" tlatsa="#38bdf8" /> <mongolo x="238" y="182" mongolo-ankora="bohareng" boholo ba fonte="22" boima ba fonte="800" tlatsa="joaleMmala">100</mongolo> <mongolo x="238" y="201" mongolo-ankora="bohareng" boholo ba fonte="10" tlatsa="tsa rona(--tjhate e kgutsitseng, joaleMmala)">kakaretso</mongolo> <hantle x="360" y="96" bophara="11" bophahamo="11" tlatsa="#f97316" /> <mongolo x="378" y="105" boholo ba fonte="11" tlatsa="joaleMmala">Li-peptides 66.7</mongolo> <hantle x="360" y="124" bophara="11" bophahamo="11" tlatsa="#38bdf8" /> <mongolo x="378" y="133" boholo ba fonte="11" tlatsa="joaleMmala">Lioligonucleotides 33.3</mongolo> <mongolo x="280.0" y="366" mongolo-ankora="bohareng" boholo ba fonte="10" tlatsa="tsa rona(--tjhate e kgutsitseng, joaleMmala)">Mohloli: Lipatlisiso tsa Grand View, Peptide & Oligonucleotide CDMO Market (2026)</mongolo> </svg> </setšoantšo>
The logic-material logic ke moo mebuso e 'meli e arohanang haholo. Tataiso ea EMA e hloka khetho ea lisebelisoa tsa ho qala bakeng sa karolo ea conjugation ho lokafatsoa tlasa ICH Q11., mme e bolela hore ho kenya tshebetsong thepa e loketseng ya ho qala PEG ke karolo ya tshebetso ya tlhahiso, kahoo motsoako oa PEG o kentsoeng o kang NHS ester o ka nkoa e le oa bohareng ho e-na le boitsebiso bo qalang. (EMA guideline, e sebetsang hantle 1 Phuptjane 2026). E boetse e lebeletse litokomane tse arohaneng bakeng sa mofani e mong le e mong oa conjugation moiety kapa linker, le tlhaloso e hlophisitsoeng e hlalositsoeng ke moetsi oa peptide-conjugate.
Synthesis ea Aspirin Liphello tse sebetsang ke hore lenaneo le kenye li-label, lihokela, Liketane tsa PEG kapa mehatla ea lipid e tsamaisa projeke ea k'hemistri hammoho le projeke ea peptide. The 2025 Tafole ea papiso ea tlhahlobo e etsa hore karohano e be e hlakileng: motsoako oa lik'hemik'hale o thusa li-amino acid tseo e seng tsa tlhaho, ho ngola li-isotopic le liphetoho tse ikhethileng sebakeng sa marang-rang, athe bioloji synthesis e lekanyelitsoe ho li-amino acid tsa tlhaho ntle le haeba boenjiniere ba liphatsa tsa lefutso kapa enzymatic bo eketsoa (Zheng et al., Int. J. Mol. Sci., 2025). Ho tenyetseha hoo ke hantle seo sethala sa recombinant-expression se ke keng sa se amohela. Peptide 2 Moetsi
Ho fana ka letsoho ke bothata bo ikhethileng le mokhoa oa phetisetso, eseng bothata ba nako
Ha lenaneo la peptide le tsamaea lipakeng tsa balekane, letlotlo le fetisetsoang ke tlhaloso le mekhoa e tiisitsoeng ka mor'a eona, 'me tataiso ea ho netefatsa e laolang e arolelanoa le tsela ea biologic. Ke Q2(R2), amohetsoe 1 Pulungoana 2023 ka tokiso ea phoso 30 Pulungoana 2023, e sebetsa mekhoeng ea tlhahlobo e sebelisoang bakeng sa tlhahlobo ea tokollo le botsitso ba lintho le lihlahisoa tsa lithethefatsi, tlhahlobo e koahelang, matla, bohloeki, ho se hloeke joalo ka teko ea bongata kapa moeli, le boitsebiso, 'me e ka sebelisoa ka mokhoa o nepahetseng nakong ea tsoelo-pele ea bongaka (Ke Q2(R2), amohetsoe 1 Pulungoana 2023). Bophahamo ba eona bo hlalosoa ka mofuta oa tšebeliso ho fapana le mofuta oa molek'hule.
Lehlakore le ikhethileng la peptide la sephutheloana le sa tloaeleha. Tataiso ea EMA e lebelletse tlhaiso-leseling e felletseng ho Module 3 Karolo 3.2.S.2.2, ho kenyelletsa le flowchart, tlhaloso ea ts'ebetso ka mehato eohle ea ts'ebetso, lisebelisoa tse tala le taolo ea ts'ebetso ea tlhahiso, 'me e hloka mehato eohle ea ho kopanya e bohareng ho tsoa ho lisebelisoa tse hlalositsoeng tse lokelang ho etsoa tlas'a GMP (EMA guideline, e sebetsang hantle 1 Phuptjane 2026). Bakeng sa peptide e kopaneng, sephutheloana seo se boetse se na le tlhaloso ea k'hemistri ea conjugation le litokomane tsa mofani oa thepa bakeng sa karolo e 'ngoe le e 'ngoe ea conjugation kapa linker..
Taolo ea likokoana-hloko le endotoxin e baloa, ha e lokisoe. Moeli oa endotoxin o nkuoa joalo ka K/M, moo K 5 EU/kg/hora bakeng sa litsela tse ngata tsa batsoali, 0.2 EU/kg/hora bakeng sa intrathecal le 100 EU/m²/hora bakeng sa tšebeliso ea sebaka sa 'mele, ka M tekanyo e phahameng e khothaletsoang ea motho ka k'hilograma ka hora (USP General Khaolo <85>, khaolo ea joale, kgutlisitsoe 2026). Teko ea sterility tlas'a USP <71> ke boleng: Custom Pna Synthesis e lemoha tšoaetso ea likokoana-hloko 'me ha e bontše ho hloeka ka ho feletseng kapa ho lekanya tšoaetso (USP <71> Liteko tsa ho beleha, mongolo wa ho dumellana). Ha ho moeli o tsamaeang joalo ka nomoro tokomaneng ea phetisetso; ho tsamaea ka bobeli joalo ka mekhoa le lipalo.
Bopaki ha bo tšehetse tekanyetso ea ho hloleha ha phetisetso kapa tieho. Ha ho palo ea mantlha kapa e hlahlobiloeng ke balekane bakeng sa litefiso tsa ho hloleha ha phetisetso ea theknoloji e fumanoeng, kahoo kotsi e phehoa molemo ka ho fetisisa ho tloha mochine oa taolo: tlhaloso, mekhoa e netefalitsoeng le tlhaloso ea ts'ebetso ea GMP ke seo sebaka se amohelang se tlamehang ho se hlahisa, 'me ho phethahala ha bona ho etsa qeto ea hore na lenaneo le hahuoa bocha hakae.
Molao oa liqeto bakeng sa litlhahlobo tse kopanetsoeng
Molao o ka tlase o fetola moeli oa taolo tekong ea balekane. E ngotsoe e le lethathamo la haeba / joale e le hore e ka sebelisoa ka ho toba tlhahlobisong ea barekisi.
Haeba mokhethoa e le peptide e entsoeng ka lik'hemik'hale ea hoo e batlang e le 50 mesaletsa kapa ka tlase ho moo ntle le phetoho ea poso, joale setsebi sa synthesis le analytics molekane ea tšoanelehang, 'me tsela e kopanetsoeng e kopantsoeng ke sebaka se fosahetseng sa ho kena.
Bakeng sa moaho o fetotsoeng, tsebahatsa k'hemistri e amehang ea conjugation, tse khethehileng tsa sebaka, lisebelisoa tsa ho qala le litšila tse ka bang teng. Litaolo tsa mahala tsa PEG kapa li-attachments tse ngata tsa PEG li sebetsa ha PEG chemistry e ameha, eseng ka bo eona ho label e 'ngoe le e 'ngoe ea isotope kapa masalla a sa tloaelehang.
Haeba tatellano e tseba likarolo tse thata, ebe u tsamaisa ho khoneha le ho hlahloba tsela pele tsela e lokisoa, hobane 30 couplings at 99% ka mohato o sebetsang hantle boloka feela ka 74% ea ketane pele ho tlhoekiso (Almanaka ea Pharma, 18 Mots'eanong 2026).
Haeba lenaneo ke recombinant biologic, joale mohlala o kopantsoeng ke foreimi e nepahetseng, 'me litlhoko tse ikhethileng tsa peptide le ho kopanya sengoloa sena ha li sebetse.
Boemo ba mmaraka bo tšehetsa ho tšoara mananeo a peptide e le qeto e ikhethileng ea ho reka ho fapana le karoloana ea biologics.. Mmaraka oa peptide le oligonucleotide CDMO e ne e le USD 3.1 limilione tse likete ho 2025 mme e lebeletsoe esale pele ho USD 8.1 limilione tse likete ka 2033 ho a 12.9% CAGR, e nang le li-peptide tse tšoereng 66.7% ea 2025 chelete e kenang (Lipatlisiso tsa Grand View, 2026 khatiso, 2025 selemo sa motheo). Lipalo ka bobeli li tsoa ho morekisi oa tlaleho, 'me nomoro ea CDMO e akaretsa li-peptide le li-oligonucleotide li kopantsoe. Mmaraka o pharalletseng oa kalafo ea peptide e ne e le USD 140.9 limilione tse likete ho 2025, esale pele ho USD 294.6 limilione tse likete ka 2033 ka 8.7% CAGR (Lipatlisiso tsa Grand View, 2026 khatiso, 2025 selemo sa motheo). Mmaraka oa biologics CDMO oo mohlala o kopaneng o lutseng ho ona o hakanngoa ho USD 62 limilione tse likete tse nang le 11.7% CAGR (GlobalData ka GlobeNewswire, 14 Mphalane 2026). Ka boraro ke mehlala ea barekisi ba litlaleho. Oligopeptide Synthesis
Lipotso Tse Botsoang Khafetsa
Etsa linako tseo Lonza a li phatlalalitseng li sebetsa lenaneong la peptide?
Che, hobane oache eo litekanyetso tsa nako li qala phetisong ea DNA, 'me liforomo tse boletsoeng boitsebisong bo le bong li kopane: li-antibodies tsa monoclonal, bispecifics le liprotheine tsa Fc-fusion (Leqephe la lenaneo la Lonza DNA-to-IND, e se nang nako, kgutlisitsoe 2026). Peptide e entsoeng ka lik'hemik'hale ha ho mohla e fetang mohato oo, kahoo kemiso ha se palo eo sehlopha sa peptide se ka e alimang. Se fetisang lipakeng tsa tse peli ke sebaka sa taolo, eseng tsela kapa almanaka.
Na setsebi se ka tsamaisa lenaneo ho ea IND ntle le mofani oa thepa e kopanetsoeng?
Ee. Module 3 le q2(R2) ditlamo ha di fetohe ka boholo ba molekane, kahoo phapang ha se hore na ho faeloa eng empa ke mang ea tšoereng litlhaloso le mokhoa o netefalitsoeng o behiloeng ho file. Setsebi se ka tšoara ka bobeli, ha feela ho sibolloa ha peptide handoff e ngotsoe e le phetiso e laoloang eseng e sa reroang. Seo mofani ea kopanetsoeng a se eketsang ke boiketlo ba ho hokahanya, eseng karolo ea taolo eo setsebi se ke keng sa e nka.
Ho thoe'ng haeba lenaneo le se le ntse le le tseleng e kopanetsoeng?
Fetisetsa tlhaloso, mekhoa le lihlopha tsa ho bapisa ho e-na le ho qala bocha. Ho qala bocha ho lahla nalane ea tlhahlobo e tšehetsang lintlha, le ho e haha bocha ho bitsa chelete e ngata ho feta ho e tsamaisa. Sephutheloana sa phetisetso ke karolo ea mosebetsi: meeli e itseng ea sehlahisoa, mekhoa e tiisitsoeng ea tokollo le botsitso, le tlhaloso ea ts'ebetso e bontšang moo boitsebiso bo hlalositsoeng bo qalang bo lutseng teng.
Qetello
Lenaneo la peptide ha le futse moralo oa litšila oa molek'hule o monyane, 'me ha e futsitse ea biologic. Ke Q3A(R2) ha e kenyeletse li-peptide, ICH Q6B ha e kenyeletse li-peptide tsa maiketsetso, le tataiso ea EMA e sebetsa hantle 1 Phuptjane 2026 e fana ka moralo o ikhethileng oa peptide sebakeng sa bona, le Ph. EUR. 2034 menyako le meeli e tobileng ea sehlahisoa. Eo ke 'nete ea sebopeho ka mor'a potso ea kopanelo, 'me e ikemetse ho nako ea morekisi ofe kapa ofe.
Mohlala o kopantsoeng oa DNA-to-IND ke karabo e lumellanang bothateng bo kopanetsoeng. Lihlopha tsa eona tse bitsoang limolek'hule ke mAbs, bispecifics le liprotheine tsa Fc-fusion, lintlha tsa eona tsa ho kena li qala kahong ea vector, 'me oache ea eona e qala phetisong ea DNA. Peptide e entsoeng ka lik'hemik'hale ha e na tse ling tsa lintho tseo, kahoo potso e loketseng e arajoa pele litšenyehelo kapa lebelo le kena lipuisanong.
Mohato o latelang ke tlhahlobo ea ho khoneha ho tatellano e khethehileng, matha pele tsela e lokisoa. Kotsi ea ho kopanya boemo ba tatellano, chemistry ea phetoho, sepheo sa sekala le moralo o sebetsang oa lintlha o etsa qeto ea hore na molekane ea khethehileng ke khetho e nepahetseng, le arithmetic ea per-step yield e etsa hore tlhahlobo eo e be theko e tlase haholo nakong ea pele..
